Table 3.
COVID-19 specific features and treatment details in the study population
| KTx group n = 29 |
Dx group n = 17 |
|
|---|---|---|
| Diagnosis of COVID-19, n | ||
| Positive PCR test | 27 | 17 |
| Positive IgM test | 2 | 0 |
| Possible source of COVID-19, n | ||
| Household | 22 | 10 |
| Healthcare | 0 | 2 |
| Unknown | 7 | 5 |
| Presenting symptoms, n | ||
| Fever | 7 | 9 |
| Cough | 7 | 2 |
| Weakness or myalgia | 9 | 6 |
| Headache | 5 | 4 |
| Gastrointestinal symptoms | 5 | 2 |
| Upper respiratory tract symptoms | 3 | 4 |
| Shortness of breath or hypoxia | 4 | 2 |
| Severity of the disease, n | ||
| Asymptomatic disease | 12 | 3 |
| Mild disease | 14 | 12 |
| Moderate disease | 2 | 0 |
| Severe disease | 1 | 1 |
| Critical illness | 0 | 1 |
| Abnormal radiologic findings, n/N | 8/19 | 6/15 |
| Lymphopenia (< 1500 cells/µL), n/N | 9/22 | 10/16 |
| Respiratory support, n | ||
| No respiratory support | 26 | 15 |
| Oxygen treatment | 3 | 1 |
| Mechanical ventilation | 0 | 1 |
| Drug treatment, n | ||
| Favipiravir | 12 | 3 |
| Hydroxychloroquine | 2 | 5 |
| Antibiotics* | 4 | 8 |
| Oseltamivir | 1 | 0 |
| IVIG | 3 | 1 |
| Immunosuppressive modification, n | 18 | |
| Mycophenolate withdrawal | 9 | |
| Mycophenolate dose reduction | 9 | |
| TAC withdrawal or dose reduction | 2 | |
| Increase in steroid dose | 4 | |
| Hospitalization**, n | 8 | 14 |
| ICU admission, n | 3 | 1 |
| Outcome, n | ||
| Recovery | 29 | 16 |
| Death | 0 | 1 |
KTx kidney transplantation, Dx dialysis, PCR polymerase chain reaction, IVIG intravenous immunoglobulin, TAC tacrolimus, ICU intensive care unit
*P = 0.019; **P = 0.001 using Fisher’s exact test, other parameters did not differ between the two groups